nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—kidney cancer	0.202	0.54	CbGaD
Lenalidomide—ABCB1—kidney cancer	0.171	0.46	CbGaD
Lenalidomide—ABCB1—Temsirolimus—kidney cancer	0.0488	0.225	CbGbCtD
Lenalidomide—ABCB1—Pazopanib—kidney cancer	0.0256	0.118	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—kidney cancer	0.0234	0.108	CbGbCtD
Lenalidomide—ABCB1—Gemcitabine—kidney cancer	0.0185	0.0856	CbGbCtD
Lenalidomide—ABCB1—Erlotinib—kidney cancer	0.0183	0.0845	CbGbCtD
Lenalidomide—ABCB1—Paclitaxel—kidney cancer	0.0167	0.0773	CbGbCtD
Lenalidomide—ABCB1—Sorafenib—kidney cancer	0.0149	0.0687	CbGbCtD
Lenalidomide—ABCB1—Vinblastine—kidney cancer	0.0147	0.0678	CbGbCtD
Lenalidomide—ABCB1—Vincristine—kidney cancer	0.0144	0.0667	CbGbCtD
Lenalidomide—ABCB1—Sunitinib—kidney cancer	0.012	0.0557	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—kidney cancer	0.00902	0.0417	CbGbCtD
Lenalidomide—CDH5—cortex of kidney—kidney cancer	0.00292	0.142	CbGeAlD
Lenalidomide—CDH5—cardiac atrium—kidney cancer	0.00278	0.135	CbGeAlD
Lenalidomide—PTGS2—nephron—kidney cancer	0.00273	0.132	CbGeAlD
Lenalidomide—CRBN—nephron tubule—kidney cancer	0.00217	0.105	CbGeAlD
Lenalidomide—CRBN—renal system—kidney cancer	0.00197	0.0955	CbGeAlD
Lenalidomide—CRBN—cortex of kidney—kidney cancer	0.00185	0.0899	CbGeAlD
Lenalidomide—CRBN—gonad—kidney cancer	0.00177	0.0856	CbGeAlD
Lenalidomide—CRBN—cardiac atrium—kidney cancer	0.00176	0.0855	CbGeAlD
Lenalidomide—Thalidomide—PTGS1—kidney cancer	0.000922	0.242	CrCbGaD
Lenalidomide—Thalidomide—CYP1A1—kidney cancer	0.000843	0.222	CrCbGaD
Lenalidomide—Pomalidomide—PTGS2—kidney cancer	0.000818	0.215	CrCbGaD
Lenalidomide—Pomalidomide—ABCB1—kidney cancer	0.000695	0.183	CrCbGaD
Lenalidomide—PTGS2—renal system—kidney cancer	0.000536	0.026	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—kidney cancer	0.000527	0.139	CrCbGaD
Lenalidomide—PTGS2—kidney—kidney cancer	0.000518	0.0251	CbGeAlD
Lenalidomide—ABCB1—nephron tubule—kidney cancer	0.000365	0.0177	CbGeAlD
Lenalidomide—ABCB1—renal system—kidney cancer	0.000332	0.0161	CbGeAlD
Lenalidomide—ABCB1—kidney—kidney cancer	0.000321	0.0155	CbGeAlD
Lenalidomide—ABCB1—cortex of kidney—kidney cancer	0.000312	0.0151	CbGeAlD
Lenalidomide—ABCB1—gonad—kidney cancer	0.000297	0.0144	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—kidney cancer	0.000105	0.000865	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKAP13—kidney cancer	0.000104	0.000855	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP2—kidney cancer	0.000104	0.000855	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—kidney cancer	0.000102	0.000841	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL13—kidney cancer	0.000102	0.000841	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	9.63e-05	0.000793	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GRB7—kidney cancer	9.5e-05	0.000782	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ANXA1—kidney cancer	9.43e-05	0.000777	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ITPR2—kidney cancer	8.83e-05	0.000727	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—kidney cancer	8.79e-05	0.000724	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—GSTM1—kidney cancer	8.58e-05	0.000707	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	8.47e-05	0.000698	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	8.47e-05	0.000698	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—kidney cancer	8.3e-05	0.000684	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	8.1e-05	0.000667	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	8.06e-05	0.000664	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	8.03e-05	0.000661	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNA1—kidney cancer	8e-05	0.000659	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EIF4EBP1—kidney cancer	7.96e-05	0.000655	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HSPB1—kidney cancer	7.96e-05	0.000655	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGR1—kidney cancer	7.92e-05	0.000653	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	7.42e-05	0.000611	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TSC1—kidney cancer	7.4e-05	0.000609	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ANXA1—kidney cancer	7.4e-05	0.000609	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PSMD7—kidney cancer	7.4e-05	0.000609	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FLT1—kidney cancer	7.16e-05	0.00059	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	6.98e-05	0.000575	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	6.95e-05	0.000573	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—kidney cancer	6.79e-05	0.000559	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PAK1—kidney cancer	6.64e-05	0.000547	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JUNB—kidney cancer	6.64e-05	0.000547	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—kidney cancer	6.61e-05	0.000544	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	6.42e-05	0.000529	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KIT—kidney cancer	6.37e-05	0.000525	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.28e-05	0.000517	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	6.22e-05	0.000512	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	6.17e-05	0.000508	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	6e-05	0.000494	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	6e-05	0.000494	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—kidney cancer	5.8e-05	0.000478	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	5.76e-05	0.000475	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	5.76e-05	0.000475	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	5.69e-05	0.000469	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	5.68e-05	0.000468	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	5.58e-05	0.00046	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	5.55e-05	0.000457	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF2—kidney cancer	5.43e-05	0.000447	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN2B—kidney cancer	5.41e-05	0.000445	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	5.39e-05	0.000444	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1R—kidney cancer	5.25e-05	0.000432	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	5.25e-05	0.000432	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—kidney cancer	5.17e-05	0.000426	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	5e-05	0.000412	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	4.95e-05	0.000408	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—kidney cancer	4.87e-05	0.000401	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—RELA—kidney cancer	4.8e-05	0.000395	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	4.73e-05	0.00039	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	4.69e-05	0.000386	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—kidney cancer	4.58e-05	0.000377	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	4.58e-05	0.000377	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	4.55e-05	0.000375	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—kidney cancer	4.37e-05	0.00036	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HIF1A—kidney cancer	4.32e-05	0.000356	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TSC2—kidney cancer	4.31e-05	0.000355	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KDR—kidney cancer	4.13e-05	0.00034	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	4.08e-05	0.000336	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	4.08e-05	0.000336	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ACY1—kidney cancer	4.03e-05	0.000332	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCBL1—kidney cancer	3.85e-05	0.000317	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	3.83e-05	0.000315	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	3.82e-05	0.000315	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APC—kidney cancer	3.81e-05	0.000314	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KIT—kidney cancer	3.81e-05	0.000314	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	3.75e-05	0.000309	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—POMC—kidney cancer	3.62e-05	0.000299	CbGpPWpGaD
Lenalidomide—Vomiting—Sorafenib—kidney cancer	3.58e-05	0.000135	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BRAF—kidney cancer	3.58e-05	0.000295	CbGpPWpGaD
Lenalidomide—Abdominal pain upper—Doxorubicin—kidney cancer	3.58e-05	0.000135	CcSEcCtD
Lenalidomide—Nervous system disorder—Paclitaxel—kidney cancer	3.57e-05	0.000135	CcSEcCtD
Lenalidomide—Hypokalaemia—Doxorubicin—kidney cancer	3.56e-05	0.000135	CcSEcCtD
Lenalidomide—Thrombocytopenia—Paclitaxel—kidney cancer	3.56e-05	0.000135	CcSEcCtD
Lenalidomide—Tachycardia—Paclitaxel—kidney cancer	3.55e-05	0.000134	CcSEcCtD
Lenalidomide—Rash—Sorafenib—kidney cancer	3.55e-05	0.000134	CcSEcCtD
Lenalidomide—Dermatitis—Sorafenib—kidney cancer	3.55e-05	0.000134	CcSEcCtD
Lenalidomide—Back pain—Capecitabine—kidney cancer	3.54e-05	0.000134	CcSEcCtD
Lenalidomide—Breast disorder—Doxorubicin—kidney cancer	3.54e-05	0.000134	CcSEcCtD
Lenalidomide—Skin disorder—Paclitaxel—kidney cancer	3.54e-05	0.000134	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	3.53e-05	0.000133	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	3.53e-05	0.000133	CcSEcCtD
Lenalidomide—Headache—Sorafenib—kidney cancer	3.53e-05	0.000133	CcSEcCtD
Lenalidomide—Muscle spasms—Capecitabine—kidney cancer	3.52e-05	0.000133	CcSEcCtD
Lenalidomide—Hyperhidrosis—Paclitaxel—kidney cancer	3.52e-05	0.000133	CcSEcCtD
Lenalidomide—Diarrhoea—Dactinomycin—kidney cancer	3.51e-05	0.000133	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—kidney cancer	3.51e-05	0.000289	CbGpPWpGaD
Lenalidomide—Nasopharyngitis—Doxorubicin—kidney cancer	3.5e-05	0.000132	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—kidney cancer	3.49e-05	0.000288	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AMER1—kidney cancer	3.48e-05	0.000287	CbGpPWpGaD
Lenalidomide—Anorexia—Paclitaxel—kidney cancer	3.47e-05	0.000131	CcSEcCtD
Lenalidomide—Gastritis—Doxorubicin—kidney cancer	3.47e-05	0.000131	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Doxorubicin—kidney cancer	3.45e-05	0.00013	CcSEcCtD
Lenalidomide—Muscular weakness—Doxorubicin—kidney cancer	3.45e-05	0.00013	CcSEcCtD
Lenalidomide—Vision blurred—Capecitabine—kidney cancer	3.45e-05	0.00013	CcSEcCtD
Lenalidomide—Vomiting—Sunitinib—kidney cancer	3.44e-05	0.00013	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.44e-05	0.000283	CbGpPWpGaD
Lenalidomide—Body temperature increased—Gemcitabine—kidney cancer	3.44e-05	0.00013	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PDHB—kidney cancer	3.43e-05	0.000283	CbGpPWpGaD
Lenalidomide—Tremor—Capecitabine—kidney cancer	3.43e-05	0.000129	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—kidney cancer	3.42e-05	0.000281	CbGpPWpGaD
Lenalidomide—Rash—Sunitinib—kidney cancer	3.42e-05	0.000129	CcSEcCtD
Lenalidomide—Dermatitis—Sunitinib—kidney cancer	3.41e-05	0.000129	CcSEcCtD
Lenalidomide—Abdominal distension—Doxorubicin—kidney cancer	3.41e-05	0.000129	CcSEcCtD
Lenalidomide—Hypotension—Paclitaxel—kidney cancer	3.4e-05	0.000128	CcSEcCtD
Lenalidomide—Ill-defined disorder—Capecitabine—kidney cancer	3.4e-05	0.000128	CcSEcCtD
Lenalidomide—Headache—Sunitinib—kidney cancer	3.39e-05	0.000128	CcSEcCtD
Lenalidomide—Influenza—Doxorubicin—kidney cancer	3.39e-05	0.000128	CcSEcCtD
Lenalidomide—Asthma—Doxorubicin—kidney cancer	3.39e-05	0.000128	CcSEcCtD
Lenalidomide—Dysphagia—Doxorubicin—kidney cancer	3.39e-05	0.000128	CcSEcCtD
Lenalidomide—Anaemia—Capecitabine—kidney cancer	3.38e-05	0.000128	CcSEcCtD
Lenalidomide—Hypersensitivity—Vincristine—kidney cancer	3.38e-05	0.000128	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	3.35e-05	0.000276	CbGpPWpGaD
Lenalidomide—Nausea—Sorafenib—kidney cancer	3.34e-05	0.000126	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—kidney cancer	3.34e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—kidney cancer	3.33e-05	0.000274	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	3.32e-05	0.000274	CbGpPWpGaD
Lenalidomide—Pancreatitis—Doxorubicin—kidney cancer	3.32e-05	0.000125	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.32e-05	0.000125	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	3.3e-05	0.000272	CbGpPWpGaD
Lenalidomide—Malaise—Capecitabine—kidney cancer	3.3e-05	0.000125	CcSEcCtD
Lenalidomide—Angina pectoris—Doxorubicin—kidney cancer	3.3e-05	0.000125	CcSEcCtD
Lenalidomide—Insomnia—Paclitaxel—kidney cancer	3.29e-05	0.000124	CcSEcCtD
Lenalidomide—Vertigo—Capecitabine—kidney cancer	3.29e-05	0.000124	CcSEcCtD
Lenalidomide—Asthenia—Vincristine—kidney cancer	3.29e-05	0.000124	CcSEcCtD
Lenalidomide—Syncope—Capecitabine—kidney cancer	3.28e-05	0.000124	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	3.28e-05	0.00027	CbGpPWpGaD
Lenalidomide—Leukopenia—Capecitabine—kidney cancer	3.28e-05	0.000124	CcSEcCtD
Lenalidomide—Paraesthesia—Paclitaxel—kidney cancer	3.27e-05	0.000123	CcSEcCtD
Lenalidomide—Vomiting—Dactinomycin—kidney cancer	3.26e-05	0.000123	CcSEcCtD
Lenalidomide—Bronchitis—Doxorubicin—kidney cancer	3.26e-05	0.000123	CcSEcCtD
Lenalidomide—Dyspnoea—Paclitaxel—kidney cancer	3.24e-05	0.000123	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—kidney cancer	3.24e-05	0.000267	CbGpPWpGaD
Lenalidomide—Somnolence—Paclitaxel—kidney cancer	3.24e-05	0.000122	CcSEcCtD
Lenalidomide—Palpitations—Capecitabine—kidney cancer	3.23e-05	0.000122	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—kidney cancer	3.23e-05	0.000122	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CCBL1—kidney cancer	3.22e-05	0.000266	CbGpPWpGaD
Lenalidomide—Nausea—Sunitinib—kidney cancer	3.22e-05	0.000122	CcSEcCtD
Lenalidomide—Loss of consciousness—Capecitabine—kidney cancer	3.22e-05	0.000121	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—kidney cancer	3.22e-05	0.000121	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.21e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.21e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.21e-05	0.000264	CbGpPWpGaD
Lenalidomide—Dyspepsia—Paclitaxel—kidney cancer	3.2e-05	0.000121	CcSEcCtD
Lenalidomide—Cough—Capecitabine—kidney cancer	3.19e-05	0.000121	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—kidney cancer	3.17e-05	0.00012	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—kidney cancer	3.17e-05	0.00012	CcSEcCtD
Lenalidomide—Decreased appetite—Paclitaxel—kidney cancer	3.16e-05	0.000119	CcSEcCtD
Lenalidomide—Hypertension—Capecitabine—kidney cancer	3.16e-05	0.000119	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—kidney cancer	3.15e-05	0.000119	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.14e-05	0.000119	CcSEcCtD
Lenalidomide—Fatigue—Paclitaxel—kidney cancer	3.14e-05	0.000119	CcSEcCtD
Lenalidomide—Diarrhoea—Vincristine—kidney cancer	3.14e-05	0.000118	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—kidney cancer	3.13e-05	0.000118	CcSEcCtD
Lenalidomide—Asthenia—Gemcitabine—kidney cancer	3.12e-05	0.000118	CcSEcCtD
Lenalidomide—Chest pain—Capecitabine—kidney cancer	3.12e-05	0.000118	CcSEcCtD
Lenalidomide—Arthralgia—Capecitabine—kidney cancer	3.12e-05	0.000118	CcSEcCtD
Lenalidomide—Myalgia—Capecitabine—kidney cancer	3.12e-05	0.000118	CcSEcCtD
Lenalidomide—Pain—Paclitaxel—kidney cancer	3.11e-05	0.000118	CcSEcCtD
Lenalidomide—Constipation—Paclitaxel—kidney cancer	3.11e-05	0.000118	CcSEcCtD
Lenalidomide—Anxiety—Capecitabine—kidney cancer	3.1e-05	0.000117	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.09e-05	0.000117	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—kidney cancer	3.09e-05	0.000117	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—kidney cancer	3.08e-05	0.000116	CcSEcCtD
Lenalidomide—Discomfort—Capecitabine—kidney cancer	3.08e-05	0.000116	CcSEcCtD
Lenalidomide—Pruritus—Gemcitabine—kidney cancer	3.08e-05	0.000116	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—kidney cancer	3.06e-05	0.000116	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—kidney cancer	3.05e-05	0.000115	CcSEcCtD
Lenalidomide—Dry mouth—Capecitabine—kidney cancer	3.05e-05	0.000115	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—kidney cancer	3.05e-05	0.000115	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—kidney cancer	3.04e-05	0.000115	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—kidney cancer	3.03e-05	0.000114	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—kidney cancer	3.02e-05	0.000114	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—kidney cancer	3.02e-05	0.000114	CcSEcCtD
Lenalidomide—Confusional state—Capecitabine—kidney cancer	3.01e-05	0.000114	CcSEcCtD
Lenalidomide—Feeling abnormal—Paclitaxel—kidney cancer	3e-05	0.000113	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	2.99e-05	0.000113	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RAF1—kidney cancer	2.99e-05	0.000246	CbGpPWpGaD
Lenalidomide—Oedema—Capecitabine—kidney cancer	2.99e-05	0.000113	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Paclitaxel—kidney cancer	2.98e-05	0.000112	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RELA—kidney cancer	2.98e-05	0.000245	CbGpPWpGaD
Lenalidomide—Diarrhoea—Gemcitabine—kidney cancer	2.97e-05	0.000112	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—kidney cancer	2.97e-05	0.000112	CcSEcCtD
Lenalidomide—Infection—Capecitabine—kidney cancer	2.97e-05	0.000112	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—kidney cancer	2.96e-05	0.000112	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—kidney cancer	2.96e-05	0.000244	CbGpPWpGaD
Lenalidomide—Stomatitis—Doxorubicin—kidney cancer	2.94e-05	0.000111	CcSEcCtD
Lenalidomide—Shock—Capecitabine—kidney cancer	2.94e-05	0.000111	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—kidney cancer	2.93e-05	0.000111	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—kidney cancer	2.93e-05	0.000111	CcSEcCtD
Lenalidomide—Nervous system disorder—Capecitabine—kidney cancer	2.93e-05	0.000111	CcSEcCtD
Lenalidomide—Thrombocytopenia—Capecitabine—kidney cancer	2.92e-05	0.00011	CcSEcCtD
Lenalidomide—PTGS2—Disease—GPC3—kidney cancer	2.92e-05	0.00024	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MTOR—kidney cancer	2.92e-05	0.00024	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.92e-05	0.00024	CbGpPWpGaD
Lenalidomide—Tachycardia—Capecitabine—kidney cancer	2.91e-05	0.00011	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—kidney cancer	2.91e-05	0.00011	CcSEcCtD
Lenalidomide—Skin disorder—Capecitabine—kidney cancer	2.9e-05	0.00011	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—kidney cancer	2.89e-05	0.000109	CcSEcCtD
Lenalidomide—Urticaria—Paclitaxel—kidney cancer	2.89e-05	0.000109	CcSEcCtD
Lenalidomide—Rash—Vincristine—kidney cancer	2.89e-05	0.000109	CcSEcCtD
Lenalidomide—Hyperhidrosis—Capecitabine—kidney cancer	2.89e-05	0.000109	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—kidney cancer	2.89e-05	0.000109	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—kidney cancer	2.88e-05	0.000109	CcSEcCtD
Lenalidomide—Body temperature increased—Paclitaxel—kidney cancer	2.88e-05	0.000109	CcSEcCtD
Lenalidomide—Abdominal pain—Paclitaxel—kidney cancer	2.88e-05	0.000109	CcSEcCtD
Lenalidomide—Headache—Vincristine—kidney cancer	2.87e-05	0.000108	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ACY1—kidney cancer	2.86e-05	0.000236	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Doxorubicin—kidney cancer	2.85e-05	0.000108	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—kidney cancer	2.85e-05	0.000108	CcSEcCtD
Lenalidomide—Anorexia—Capecitabine—kidney cancer	2.85e-05	0.000108	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—kidney cancer	2.84e-05	0.000234	CbGpPWpGaD
Lenalidomide—Sinusitis—Doxorubicin—kidney cancer	2.83e-05	0.000107	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—kidney cancer	2.82e-05	0.000106	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PPAT—kidney cancer	2.8e-05	0.00023	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GLIPR1—kidney cancer	2.8e-05	0.00023	CbGpPWpGaD
Lenalidomide—Hypotension—Capecitabine—kidney cancer	2.79e-05	0.000105	CcSEcCtD
Lenalidomide—Vomiting—Gemcitabine—kidney cancer	2.76e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.76e-05	0.000227	CbGpPWpGaD
Lenalidomide—Bradycardia—Doxorubicin—kidney cancer	2.76e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—kidney cancer	2.75e-05	0.000226	CbGpPWpGaD
Lenalidomide—Rash—Gemcitabine—kidney cancer	2.74e-05	0.000104	CcSEcCtD
Lenalidomide—Dermatitis—Gemcitabine—kidney cancer	2.74e-05	0.000103	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—kidney cancer	2.74e-05	0.000226	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.73e-05	0.000225	CbGpPWpGaD
Lenalidomide—Haemoglobin—Doxorubicin—kidney cancer	2.72e-05	0.000103	CcSEcCtD
Lenalidomide—Headache—Gemcitabine—kidney cancer	2.72e-05	0.000103	CcSEcCtD
Lenalidomide—Nausea—Vincristine—kidney cancer	2.72e-05	0.000103	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.72e-05	0.000103	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—kidney cancer	2.72e-05	0.000103	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—kidney cancer	2.71e-05	0.000102	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—kidney cancer	2.71e-05	0.000102	CcSEcCtD
Lenalidomide—Insomnia—Capecitabine—kidney cancer	2.7e-05	0.000102	CcSEcCtD
Lenalidomide—PTGS2—Disease—ST3GAL2—kidney cancer	2.7e-05	0.000222	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Doxorubicin—kidney cancer	2.7e-05	0.000102	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—kidney cancer	2.69e-05	0.000102	CcSEcCtD
Lenalidomide—Paraesthesia—Capecitabine—kidney cancer	2.68e-05	0.000101	CcSEcCtD
Lenalidomide—Hypersensitivity—Paclitaxel—kidney cancer	2.68e-05	0.000101	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—kidney cancer	2.68e-05	0.000221	CbGpPWpGaD
Lenalidomide—Urinary tract disorder—Doxorubicin—kidney cancer	2.68e-05	0.000101	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—kidney cancer	2.67e-05	0.00022	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Doxorubicin—kidney cancer	2.67e-05	0.000101	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—kidney cancer	2.66e-05	0.000101	CcSEcCtD
Lenalidomide—Dyspnoea—Capecitabine—kidney cancer	2.66e-05	0.000101	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—kidney cancer	2.66e-05	0.0001	CcSEcCtD
Lenalidomide—Dyspepsia—Capecitabine—kidney cancer	2.63e-05	9.93e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK1—kidney cancer	2.61e-05	0.000215	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—kidney cancer	2.61e-05	0.000215	CbGpPWpGaD
Lenalidomide—Visual impairment—Doxorubicin—kidney cancer	2.61e-05	9.86e-05	CcSEcCtD
Lenalidomide—Asthenia—Paclitaxel—kidney cancer	2.61e-05	9.86e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—JUN—kidney cancer	2.61e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APRT—kidney cancer	2.6e-05	0.000214	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FH—kidney cancer	2.6e-05	0.000214	CbGpPWpGaD
Lenalidomide—Decreased appetite—Capecitabine—kidney cancer	2.6e-05	9.81e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	2.59e-05	0.000214	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—kidney cancer	2.59e-05	0.000213	CbGpPWpGaD
Lenalidomide—Nausea—Gemcitabine—kidney cancer	2.58e-05	9.75e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Capecitabine—kidney cancer	2.58e-05	9.74e-05	CcSEcCtD
Lenalidomide—Fatigue—Capecitabine—kidney cancer	2.57e-05	9.73e-05	CcSEcCtD
Lenalidomide—Pruritus—Paclitaxel—kidney cancer	2.57e-05	9.72e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	2.56e-05	0.000211	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Doxorubicin—kidney cancer	2.56e-05	9.68e-05	CcSEcCtD
Lenalidomide—Pain—Capecitabine—kidney cancer	2.55e-05	9.65e-05	CcSEcCtD
Lenalidomide—Constipation—Capecitabine—kidney cancer	2.55e-05	9.65e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.54e-05	0.000209	CbGpPWpGaD
Lenalidomide—Eye disorder—Doxorubicin—kidney cancer	2.53e-05	9.56e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—PGK1—kidney cancer	2.53e-05	0.000208	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC5A3—kidney cancer	2.53e-05	0.000208	CbGpPWpGaD
Lenalidomide—Tinnitus—Doxorubicin—kidney cancer	2.53e-05	9.54e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—kidney cancer	2.52e-05	0.000208	CbGpPWpGaD
Lenalidomide—Flushing—Doxorubicin—kidney cancer	2.51e-05	9.5e-05	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—kidney cancer	2.51e-05	9.5e-05	CcSEcCtD
Lenalidomide—Diarrhoea—Paclitaxel—kidney cancer	2.49e-05	9.4e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—LDHB—kidney cancer	2.48e-05	0.000204	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SFRP2—kidney cancer	2.48e-05	0.000204	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Capecitabine—kidney cancer	2.46e-05	9.3e-05	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—kidney cancer	2.46e-05	9.29e-05	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—kidney cancer	2.45e-05	9.24e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GPC3—kidney cancer	2.44e-05	0.000201	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Capecitabine—kidney cancer	2.44e-05	9.22e-05	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—kidney cancer	2.44e-05	9.22e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—PDHB—kidney cancer	2.43e-05	0.0002	CbGpPWpGaD
Lenalidomide—Chills—Doxorubicin—kidney cancer	2.43e-05	9.18e-05	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—kidney cancer	2.42e-05	9.14e-05	CcSEcCtD
Lenalidomide—Dizziness—Paclitaxel—kidney cancer	2.41e-05	9.09e-05	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—kidney cancer	2.39e-05	9.04e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CA2—kidney cancer	2.38e-05	0.000196	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	2.38e-05	0.000196	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—kidney cancer	2.37e-05	8.97e-05	CcSEcCtD
Lenalidomide—Urticaria—Capecitabine—kidney cancer	2.37e-05	8.96e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Capecitabine—kidney cancer	2.36e-05	8.92e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Capecitabine—kidney cancer	2.36e-05	8.92e-05	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—kidney cancer	2.36e-05	8.91e-05	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—kidney cancer	2.36e-05	8.91e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	2.34e-05	0.000193	CbGpPWpGaD
Lenalidomide—Flatulence—Doxorubicin—kidney cancer	2.32e-05	8.78e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ALAD—kidney cancer	2.32e-05	0.000191	CbGpPWpGaD
Lenalidomide—Tension—Doxorubicin—kidney cancer	2.31e-05	8.74e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—TCEB1—kidney cancer	2.31e-05	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TCEB2—kidney cancer	2.31e-05	0.000191	CbGpPWpGaD
Lenalidomide—Vomiting—Paclitaxel—kidney cancer	2.31e-05	8.74e-05	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—kidney cancer	2.31e-05	8.72e-05	CcSEcCtD
Lenalidomide—Rash—Paclitaxel—kidney cancer	2.29e-05	8.67e-05	CcSEcCtD
Lenalidomide—Dermatitis—Paclitaxel—kidney cancer	2.29e-05	8.66e-05	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—kidney cancer	2.29e-05	8.65e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CCBL1—kidney cancer	2.29e-05	0.000188	CbGpPWpGaD
Lenalidomide—Back pain—Doxorubicin—kidney cancer	2.28e-05	8.62e-05	CcSEcCtD
Lenalidomide—Headache—Paclitaxel—kidney cancer	2.28e-05	8.61e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—kidney cancer	2.28e-05	0.000188	CbGpPWpGaD
Lenalidomide—Muscle spasms—Doxorubicin—kidney cancer	2.27e-05	8.57e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	2.27e-05	0.000187	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ST3GAL2—kidney cancer	2.26e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	2.26e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	2.24e-05	0.000185	CbGpPWpGaD
Lenalidomide—Vision blurred—Doxorubicin—kidney cancer	2.22e-05	8.4e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—ALDH1A1—kidney cancer	2.21e-05	0.000182	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Capecitabine—kidney cancer	2.2e-05	8.31e-05	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—kidney cancer	2.19e-05	0.000181	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Doxorubicin—kidney cancer	2.19e-05	8.27e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	2.19e-05	0.00018	CbGpPWpGaD
Lenalidomide—Anaemia—Doxorubicin—kidney cancer	2.18e-05	8.23e-05	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—kidney cancer	2.17e-05	8.19e-05	CcSEcCtD
Lenalidomide—Nausea—Paclitaxel—kidney cancer	2.16e-05	8.16e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—kidney cancer	2.15e-05	0.000177	CbGpPWpGaD
Lenalidomide—Asthenia—Capecitabine—kidney cancer	2.14e-05	8.09e-05	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—kidney cancer	2.13e-05	8.03e-05	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—kidney cancer	2.12e-05	8e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SLC5A3—kidney cancer	2.12e-05	0.000175	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PGK1—kidney cancer	2.12e-05	0.000175	CbGpPWpGaD
Lenalidomide—Syncope—Doxorubicin—kidney cancer	2.12e-05	7.99e-05	CcSEcCtD
Lenalidomide—Pruritus—Capecitabine—kidney cancer	2.11e-05	7.98e-05	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—kidney cancer	2.11e-05	7.97e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—kidney cancer	2.1e-05	0.000173	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—kidney cancer	2.08e-05	7.87e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—LDHB—kidney cancer	2.08e-05	0.000171	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Doxorubicin—kidney cancer	2.07e-05	7.83e-05	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—kidney cancer	2.06e-05	7.77e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MAPK1—kidney cancer	2.05e-05	0.000169	CbGpPWpGaD
Lenalidomide—Diarrhoea—Capecitabine—kidney cancer	2.04e-05	7.72e-05	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—kidney cancer	2.04e-05	7.69e-05	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—kidney cancer	2.01e-05	7.59e-05	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—kidney cancer	2.01e-05	7.59e-05	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—kidney cancer	2.01e-05	7.59e-05	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—kidney cancer	2e-05	7.56e-05	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.99e-05	7.53e-05	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—kidney cancer	1.98e-05	7.49e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—GLIPR1—kidney cancer	1.98e-05	0.000163	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPAT—kidney cancer	1.98e-05	0.000163	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.98e-05	0.000163	CbGpPWpGaD
Lenalidomide—Dizziness—Capecitabine—kidney cancer	1.98e-05	7.46e-05	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—kidney cancer	1.96e-05	7.42e-05	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—kidney cancer	1.94e-05	7.33e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KRAS—kidney cancer	1.94e-05	0.000159	CbGpPWpGaD
Lenalidomide—Oedema—Doxorubicin—kidney cancer	1.93e-05	7.27e-05	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—kidney cancer	1.91e-05	7.22e-05	CcSEcCtD
Lenalidomide—Vomiting—Capecitabine—kidney cancer	1.9e-05	7.17e-05	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—kidney cancer	1.89e-05	7.15e-05	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—kidney cancer	1.89e-05	7.13e-05	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—kidney cancer	1.88e-05	7.12e-05	CcSEcCtD
Lenalidomide—Rash—Capecitabine—kidney cancer	1.88e-05	7.11e-05	CcSEcCtD
Lenalidomide—Dermatitis—Capecitabine—kidney cancer	1.88e-05	7.11e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—RPL14—kidney cancer	1.88e-05	0.000155	CbGpPWpGaD
Lenalidomide—Tachycardia—Doxorubicin—kidney cancer	1.88e-05	7.1e-05	CcSEcCtD
Lenalidomide—Headache—Capecitabine—kidney cancer	1.87e-05	7.07e-05	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—kidney cancer	1.87e-05	7.06e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.87e-05	0.000154	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Doxorubicin—kidney cancer	1.86e-05	7.03e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—APRT—kidney cancer	1.84e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FH—kidney cancer	1.84e-05	0.000152	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.84e-05	0.000151	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—kidney cancer	1.84e-05	6.93e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.82e-05	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.82e-05	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA9—kidney cancer	1.8e-05	0.000148	CbGpPWpGaD
Lenalidomide—Hypotension—Doxorubicin—kidney cancer	1.8e-05	6.79e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—kidney cancer	1.78e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.78e-05	0.000146	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.78e-05	0.000146	CbGpPWpGaD
Lenalidomide—Nausea—Capecitabine—kidney cancer	1.77e-05	6.7e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.76e-05	0.000145	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.75e-05	6.62e-05	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—kidney cancer	1.74e-05	6.58e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—GPC3—kidney cancer	1.73e-05	0.000143	CbGpPWpGaD
Lenalidomide—Paraesthesia—Doxorubicin—kidney cancer	1.73e-05	6.53e-05	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—kidney cancer	1.72e-05	0.000142	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—kidney cancer	1.72e-05	6.48e-05	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—kidney cancer	1.71e-05	6.46e-05	CcSEcCtD
Lenalidomide—PTGS2—Disease—ITPR2—kidney cancer	1.7e-05	0.00014	CbGpPWpGaD
Lenalidomide—Dyspepsia—Doxorubicin—kidney cancer	1.69e-05	6.4e-05	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.69e-05	0.000139	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA2—kidney cancer	1.69e-05	0.000139	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.68e-05	0.000139	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.68e-05	0.000138	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—kidney cancer	1.67e-05	6.32e-05	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.66e-05	6.28e-05	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—kidney cancer	1.66e-05	6.27e-05	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—kidney cancer	1.65e-05	6.22e-05	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—kidney cancer	1.65e-05	6.22e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ALAD—kidney cancer	1.64e-05	0.000135	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.63e-05	0.000135	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.61e-05	0.000132	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.6e-05	0.000132	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.6e-05	0.000132	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.59e-05	0.000131	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—kidney cancer	1.59e-05	5.99e-05	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—kidney cancer	1.57e-05	5.95e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.57e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.55e-05	0.000128	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.54e-05	0.000127	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CRABP1—kidney cancer	1.53e-05	0.000126	CbGpPWpGaD
Lenalidomide—Urticaria—Doxorubicin—kidney cancer	1.53e-05	5.78e-05	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—kidney cancer	1.52e-05	5.75e-05	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—kidney cancer	1.52e-05	5.75e-05	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—PGK1—kidney cancer	1.5e-05	0.000124	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A3—kidney cancer	1.5e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.49e-05	0.000123	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LDHB—kidney cancer	1.47e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSMD7—kidney cancer	1.43e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ITPR2—kidney cancer	1.42e-05	0.000117	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Doxorubicin—kidney cancer	1.42e-05	5.36e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.4e-05	0.000115	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—kidney cancer	1.38e-05	5.22e-05	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—kidney cancer	1.36e-05	5.14e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.32e-05	0.000109	CbGpPWpGaD
Lenalidomide—Diarrhoea—Doxorubicin—kidney cancer	1.32e-05	4.98e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.31e-05	0.000108	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—kidney cancer	1.3e-05	0.000107	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ACHE—kidney cancer	1.3e-05	0.000107	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC2A1—kidney cancer	1.29e-05	0.000106	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.29e-05	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JUNB—kidney cancer	1.28e-05	0.000105	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA9—kidney cancer	1.28e-05	0.000105	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—kidney cancer	1.27e-05	4.81e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.26e-05	0.000104	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SCARB1—kidney cancer	1.23e-05	0.000101	CbGpPWpGaD
Lenalidomide—Vomiting—Doxorubicin—kidney cancer	1.22e-05	4.62e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PTGS1—kidney cancer	1.22e-05	0.0001	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—kidney cancer	1.21e-05	4.58e-05	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—kidney cancer	1.21e-05	4.58e-05	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—kidney cancer	1.21e-05	4.56e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—PSMD7—kidney cancer	1.19e-05	9.83e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.19e-05	9.81e-05	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—kidney cancer	1.14e-05	4.32e-05	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—BCHE—kidney cancer	1.13e-05	9.32e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—kidney cancer	1.12e-05	9.21e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.09e-05	9.01e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CRABP1—kidney cancer	1.09e-05	8.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC2A1—kidney cancer	1.08e-05	8.89e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.06e-05	8.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN2B—kidney cancer	1.04e-05	8.58e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ITPR2—kidney cancer	1.01e-05	8.32e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ACHE—kidney cancer	9.21e-06	7.58e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—kidney cancer	9.21e-06	7.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.13e-06	7.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—kidney cancer	9e-06	7.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SCARB1—kidney cancer	8.72e-06	7.18e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS1—kidney cancer	8.63e-06	7.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—kidney cancer	8.52e-06	7.02e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSMD7—kidney cancer	8.46e-06	6.97e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—kidney cancer	8.33e-06	6.86e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TSC2—kidney cancer	8.31e-06	6.84e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—kidney cancer	8.27e-06	6.81e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BCHE—kidney cancer	8.02e-06	6.61e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—kidney cancer	7.92e-06	6.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—kidney cancer	7.84e-06	6.46e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC2A1—kidney cancer	7.65e-06	6.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—kidney cancer	7.34e-06	6.04e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—kidney cancer	7.34e-06	6.04e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.3e-06	6.01e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—kidney cancer	6.89e-06	5.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.44e-06	5.31e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—kidney cancer	6.38e-06	5.26e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—kidney cancer	5.86e-06	4.83e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—POMC—kidney cancer	5.85e-06	4.82e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAF1—kidney cancer	5.76e-06	4.74e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—kidney cancer	5.7e-06	4.69e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—kidney cancer	5.62e-06	4.63e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—kidney cancer	5.61e-06	4.62e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—kidney cancer	5.56e-06	4.58e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—kidney cancer	5.27e-06	4.34e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—kidney cancer	4.98e-06	4.1e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—kidney cancer	4.86e-06	4e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—kidney cancer	4.15e-06	3.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POMC—kidney cancer	4.15e-06	3.41e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—kidney cancer	4.07e-06	3.35e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—kidney cancer	4.04e-06	3.32e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK1—kidney cancer	3.95e-06	3.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—kidney cancer	3.73e-06	3.07e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—kidney cancer	3.43e-06	2.82e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—kidney cancer	3.31e-06	2.72e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—kidney cancer	2.88e-06	2.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—kidney cancer	2.87e-06	2.36e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—kidney cancer	2.03e-06	1.68e-05	CbGpPWpGaD
